Article 12
Maspero J, et al. Clin Ther. 2008. PMID: 18803991 Clinical Trial.
Article 11
EFFICACY AND TOLERABILITY OF SALMETEROL/FLUTICASONE PROPIONATE VERSUS MONTELUKAST IN CHILDHOOD ASTHMA: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY
Article 10
Weinstein SF, et al. Allergy Asthma Proc. 2010 Jul-Aug;31(4):280-9. doi: 10.2500/aap.2010.31.3381. Epub 2010 Aug 3. PMID: 20687982.
Article 9
TWELVE-WEEK EFFICACY AND SAFETY STUDY OF MOMETASONE FUROATE/FORMOTEROL 200/10 MICROG AND 400/10 MICROG COMBINATION TREATMENTS IN PATIENTS WITH PERSISTENT ASTHMA PREVIOUSLY RECEIVING HIGH-DOSE INHALED CORTICOSTEROIDS
Article 8
“A CASE OF ASPERGILLUS ENDOCARDITIS WITH LONG TERM DIALYSIS”: https://www.sciencedirect.com/science/article/pii/S0735109723034472 Faiza Choudhry, Sean Dawes, Sabina Custovic, George Yassa, Sailokesh Pagadala, Franco Parodi, Dustin Harmon, Ascension Macomb-Oakland Hospital, Warren, MI, USA
Article 7
Are We Diving Too Deep With Daily COVID-19 Testing? Ronny Y.Hadid MD 1, Muhammad Syed DO 2, Noah Hochstetler DO 2, Oscar F. Parodi Ortiz De Villate MD1 1 Department of Pulmonary and Critical Care Medicine, Ascension Macomb-Oakland Hospital, Warren, MI,2 Department of Internal Medicine, Ascension Macomb-Oakland Hospital, Warren, MI
Article 6
BATURA: A Comparison of PT027 vs PT007 Used as Needed in Participants with Asthma
Article 5
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 52 WEEKS IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA_EXHALE-4
Article 4
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF DEXPRAMIPEXOLE ADMINISTERED ORALLY FOR 52 WEEKS IN PARTICIPANTS WITH SEVERE EOSINOPHILIC ASTHMA _EXHALE-3
Article 3
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SAR440340/REGN3500/ITEPEKIMAB (ANTI- IL-33 MAB) IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)